DR. REDDY S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad 500034. Telangana, India. CONTACT INVESTOR RELATIONS MEDIA RELATIONS SAUNAK SAVLA saunaks@drreddys.com (Ph: +91-40- 49002135) CALVIN PRINTER cal

Dr. Reddy s Laboratories announces the launch of

Raloxifene HCl Tablets, USP in the U.S. Market

Hyderabad, India and Princeton, NJ, USA. 10 November 2016 Dr. Reddy s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today

that it has launched Raloxifene hydrochloride tablets in 60 mg, a therapeutic equivalent generic version of Evista (raloxifene hydrochloride) tablets in the United States market, approved by

the U.S. Food & Drug Administration (USFDA).

The Evista brand and generic had U.S. sales of

approximately $265 million MAT for the most recent twelve months ending in September 2016 according to IMS Health*.

Dr. Reddy s Raloxifene tablets

are available in 60 mg in bottle count sizes of 30, 100 and 1,000.

Evista is a registered

trademark of Eli Lilly and Company.

* IMS National Sales Perspective: Retail and Non-Retail MAT September 2016

About Dr. Reddy s: Dr.

Reddy s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses Pharmaceutical

Services & Active Ingredients, Global Generics and Proprietary Products Dr. Reddy s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.

Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy s operates in markets across the globe. Our major markets include USA, India, Russia & CIS

countries, and Europe. For more information, log on to: www.drreddys.com

press release may include statements of future expectations and other forward-looking statements that are based on the management s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual

results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words may , will , should ,

expects , plans , intends , anticipates , believes , estimates , predicts , potential , or continue and similar expressions identify forward-looking

statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates

, interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and

regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues.

The company assumes no obligation to update any information contained herein.